Showing results (951-960 of 991) with videos related to

Sort By:
Pageof 100
The Oncologist|August 1, 2020
Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise CentersLucia Nappi, Margaret Ottaviano, Pasquale Rescigno, et al.
Neurosurgery|July 28, 2025
Lumbar Drain Infection Rates: A Comprehensive Risk Factor Analysis From a Multicenter Retrospective Study of 1000+ CasesAsfand Baig Mirza, Maria Alexandra Velicu, Amisha Vastani, et al.
JTO Clinical and Research Reports|February 16, 2023
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC RegistryGiannis Mountzios, David Planchard, Giulio Metro, et al.
Journal for Immunotherapy of Cancer|February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinationsAlessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.
Frontiers in Oncology|February 27, 2024
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: <i>post-hoc</i> analysis of the Meet-URO 15 studyVeronica Murianni, Alessio Signori, Sebastiano Buti, et al.
Journal of Translational Medicine|September 30, 2022
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 studySara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.
Frontiers in Oncology|October 10, 2022
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysisSara Elena Rebuzzi, Alessio Signori, Marco Stellato, et al.
Clinical Genitourinary Cancer|November 27, 2024
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 StudyBrigida Anna Maiorano, Martina Catalano, Chiara Mercinelli, et al.
Cancer Immunology, Immunotherapy : CII|February 3, 2026
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 studyMichele Maffezzoli, Alessio Signori, Alessandro Acunzo, et al.
Critical Reviews in Oncology/Hematology|April 25, 2019
Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia MedicaGiuseppe Luigi Banna, Nicola Nicolai, Giovannella Palmieri, et al.
Pageof 100